5500 Reported lives saved with the help of EVZIO based on voluntary reports from recipients of donated product
5500 Reported lives saved with the help of EVZIO based on voluntary reports from recipients of donated product
†Terms and Conditions: Only valid for commercially insured patients in the 50 United States and DC through the direct delivery service. Not eligible if prescriptions are paid for in part/full by state or federally funded program(s), like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or Tricare, and where prohibited by law. OFFER IS NOT INSURANCE. Offer cannot be sold, purchased, traded, transferred, and cannot be combined with any other offer. Offer may change at any time, without notice. Call (877) 438-9463 for questions regarding eligibility.
EVZIO—an auto-injector designed to be easy to use—provides simple, on-the-spot voice and visual guidance to help those with no medical training administer naloxone during an opioid overdose. EVZIO is not a substitute for emergency medical care.
Patients should seek emergency medical assistance immediately after use.
*Sample story.
Anywhere opioids are present, so is the risk for an opioid overdose.1
All commercially insured patients pay absolutely nothing out of pocket for EVZIO through the direct-delivery service.†
To learn more, click the link below that best describes your patient’s needs:
†See full Terms and Conditions.
EVZIO—an auto-injector designed to be easy to use. EVZIO is not a substitute for emergency medical care.
EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.
EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.
Seek emergency medical assistance immediately after use. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
The following warnings and precautions should be taken when administering EVZIO:
The following adverse reactions were most commonly observed in EVZIO clinical studies: dizziness and injection site erythema.
Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated signs and symptoms of opioid withdrawal including: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In the neonate, opioid withdrawal signs and symptoms also included: convulsions, excessive crying, and hyperactive reflexes.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click for full Prescribing Information and Patient Information.
EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.
EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.